The value of diagnostic testing for parents of children with rare genetic diseases |
| |
| Affiliation: | 1. Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada;2. Health Economics Research Unit, University of Aberdeen, Aberdeen, Scotland;3. Evidera, Inc., London, UK;4. Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada;5. Department of Genetics and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada;1. Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada;2. Health Economics Research Unit, University of Aberdeen, Aberdeen, Scotland;3. Evidera, Inc., London, UK;4. Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, Canada;5. Department of Genetics and Alberta Children’s Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada |
| |
| Abstract: | PurposeExome sequencing (ES) can rapidly identify disease-causing variants responsible for rare, single-gene diseases, and potentially reduce the duration of the diagnostic odyssey. Our study examines how parents and families value ES.MethodsWe developed a discrete choice experiment (DCE) survey that was administered to parents of children with rare diseases. The DCE included 14 choice tasks with 6 attributes and 3 alternatives. A valuation-space model was used to estimate willingness to pay, willingness to wait for test results, and minimum acceptable chance of a diagnosis for changes in each attribute.ResultsThere were n = 319 respondents of whom 89% reported their child had genetic testing, and 66% reported their child had a diagnosis. Twenty-six percent reported that their child had been offered ES. Parents were willing to pay CAD$6590 (US$4943), wait 5.2 years to obtain diagnostic test results, and accept a reduction of 3.1% in the chance of a diagnosis for ES compared with operative procedures.ConclusionTimely access to ES could reduce the diagnostic odyssey and associated costs. Before ES is incorporated routinely into care for patients with rare diseases in Canada and more broadly, there must be a clear understanding of its value to patients and families. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
